股票代码：600421 股票简称：*ST华嵘 公告编号：临 2025-030 公司股票价格自 2025 年 5 月 6 日至 5 月 15 日连续八个交易日内收盘价格涨 幅偏离值累计达 35.94%，公司股价短期波动幅度较大，郑重提醒广大投资者充 分了解二级市场交易风险，切实提高风险意识，理性决策，审慎投资。 湖北华嵘控股股份有限公司 股票交易风险提示公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、生产经营情况 公司目前生产经营活动正常，主营业务未发生重大变化，不存在其他影 响公司股票交易价格异常波动的重大事项，不存在应披露而未披露的重大信 息。 二、二级市场交易风险 湖北华嵘控股股份有限公司董事会 ? 公司 2024 年度经审计的扣除非经常性损益后的净利润为负值，且扣除与主 营业务无关的业务收入和不具备商业实质的收入后的营业收入低于 3 亿元， 触及《上海证券交易所股票上市规则》第 9.3.2 条第一款第（一）项规定， 公司股票于 2025 年 4 月 29 日起实施退市风险警示。公司 202 ...

Core Viewpoint - Jiangsu Wuzhong has faced multiple negative events since 2025, including regulatory scrutiny and financial difficulties, leading to its stock being placed on risk warning status and potential delisting [1][3][5]. Group 1: Regulatory Issues - The chairman of Jiangsu Wuzhong, Qian Qunshan, received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation for suspected violations of information disclosure laws [1]. - The company has been under investigation since February 27, 2025, for similar allegations, with the CSRC deciding to initiate a case against it [3]. - A subsidiary's former legal representative was prosecuted for involvement in fraudulent activities related to export tax rebates [3]. Group 2: Financial Performance - In 2024, Jiangsu Wuzhong reported a revenue of 1.599 billion yuan, a year-on-year decrease of 28.64%, but achieved a net profit of 70.48 million yuan, marking a turnaround from losses [4]. - The pharmaceutical segment generated revenue of 1.229 billion yuan, down 33.19% year-on-year, while the medical beauty sector saw a significant increase in revenue to 330 million yuan, up 4225.65% [4]. Group 3: Corporate Governance and Internal Control - Despite a slight improvement in financial performance, Jiangsu Wuzhong has revealed serious internal control issues, pushing the company closer to delisting [5]. - The controlling shareholder, Suzhou Wuzhong Investment Holdings, held a 17.24% stake in the company as of the first quarter of 2025 [6].

Core Viewpoint - *ST Suwu is facing significant challenges, including an investigation by the China Securities Regulatory Commission (CSRC) for information disclosure violations, which has led to a risk of forced delisting and a sharp decline in stock price [2][4][10] Group 1: Regulatory Issues - The chairman of *ST Suwu, Qian Qunshan, has been notified of a formal investigation by the CSRC for suspected violations of information disclosure laws [2] - The company has been under investigation since February 2025 for information disclosure violations, and it announced a significant risk of forced delisting in April 2025 [4] - The CSRC's investigation is ongoing, and *ST Suwu has not yet received a conclusive opinion or decision regarding the investigation [7] Group 2: Financial Performance - In 2024, *ST Suwu reported revenue of 1.599 billion yuan and a net profit of 70.48 million yuan, marking a five-year high [10] - The company achieved profitability in 2024 primarily due to the sales of the "Tongyan Needle," which generated 195 million yuan in revenue with a gross margin of 82.89% [8] - Despite the positive revenue and profit figures, *ST Suwu's cash flow situation remains concerning, with a significant decline in cash reserves from 1.152 billion yuan in 2024 to 168 million yuan in Q1 2025 [10] Group 3: Cash Flow Concerns - The company is experiencing severe cash flow issues, with operating cash flow showing continuous outflows of 204 million yuan in 2023 and 275 million yuan in early 2024 [10] - As of Q1 2025, *ST Suwu's operating cash flow net amount was -924 million yuan, indicating a substantial decline year-on-year [10] - The company's short-term borrowings reached 1.304 billion yuan, creating significant short-term repayment pressure [10]

Core Viewpoint - The company is facing significant financial challenges due to the non-repayment of funds by its controlling shareholder and related parties, which could lead to severe consequences including stock suspension and delisting if not resolved promptly [1][2]. Group 1: Financial Issues - The controlling shareholder, Dongfang Shishang Investment, and its affiliates have cumulatively repaid 0 yuan of the occupied funds, with a remaining balance of approximately 387 million yuan [1]. - The company has initiated legal action regarding non-operational fund occupation through accounts receivable factoring, but the court did not support the company's claims [1]. - The company is also pursuing legal action against Beijing Tonglong Automobile Sales Co., Ltd. for the non-delivery of an AI intelligent driving training system, with the case yet to be heard [1]. Group 2: Regulatory Risks - According to the Shanghai Stock Exchange regulations, if the company fails to recover the 387 million yuan within six months (by June 19, 2025), its stock will be suspended [2]. - If the company does not complete the required rectification within two months after suspension, it will face a delisting risk warning [2]. - Continued failure to rectify the situation within the subsequent two months could lead to the termination of the company's stock listing [2].

5月13日，*ST华微（600360）发布公告称，公司已向控股股东、实际控制人发函，要求控股股东、实 际控制人及其他关联方采取现金清偿、红利抵债、以资抵债等方式限期偿还占用公司的资金约14.91亿 元。 公告称，*ST华微控股股东上海鹏盛科技实业有限公司（以下简称："上海鹏盛"）已将持有的华微电子 全部股份质押给公司全资子公司吉林麦吉柯半导体有限公司，作为其履行非经营性占用资金归还义务的 担保。该质权将全部用于补偿华微电子因资金占用事项造成的损失。 证监会责令改正 公告称，公司于 2025 年 2 月 12 日收到中国证监会吉林监管局下发的《关于对吉林华微电子股份有限公 司、上海鹏盛科技实业有限公司采取责令改正措施的决定》，ST华微控股股东上海鹏盛及其关联方以 预付设备款等名义，非经营性占用ST华微资金。 截至2024年10月15日，公司非经营性资金占用余额为14.91亿元，占公司2023年末经审计净资产的 45.70%。责令改正决定书要求，所有占用资金应在收到决定书之日起6个月内（2025 年8月12日前）归 还。 若公司未能按照责令改正要求在6 个月内清收14.91亿元被占用资金，上交所将对公司股票实施停 ...

石圣平或许未曾料到，在其入主恒立实业还不到9个月后，这家被誉为A股"不死鸟"的上市公司就要面临退市。 年报"难产" 5月7日晚，深交所向*ST恒立(000622.SZ)下发了《终止上市事先告知书》，截至4月30日，公司未在法定期限内披露过半数董事保证真实、准 确、完整的2024年年度报告，这触及了深交所规定的股票终止上市情形。 深交所拟决定终止*ST恒立股票上市交易。 此前4月29日深夜，*ST恒立就发布了一则"无法在预约日期及预计无法在法定期限内披露定期报告"的风险提示。 *ST恒立称，旭泰会所对公司2024年年度报告审计过程中，未按照双方签订的《审计业务约定书》及《总体审计策略》规定的时间、流程以及 法定程序开展审计工作，公司于2025年4月29日下午3点后才收到旭泰会所出具的正式审计报告及其他相关专项报告。 旭泰会所会计师与*ST恒立在部分业务收入确认方面存在一定分歧，如果该部分业务收入最终无法合并计算至公司总的主营业务收入，将导致 公司2024年主营业务收入低于3亿元。 不仅如此，因新余锂想和零部件公司主营业务毛利率偏低，子公司湖南恒胜计提信用减值损失增加等，这导致公司亏损增加。 *ST恒立预计202 ...

Core Viewpoint - *ST Muban has faced significant challenges in its transition from a toy manufacturer to a photovoltaic company, resulting in a drastic decline in stock price and financial performance [1][4]. Group 1: Company Background and Transition - *ST Muban, established in 2003, initially focused on educational toys and gained recognition with its "Bangbao" brand, likened to a "Chinese version of LEGO" [5]. - The company sought a "second curve" for growth due to stagnation in its toy business, leading to a controversial acquisition of Haoyuan Energy for 980 million yuan, despite its net assets being only 170 million yuan [6]. Group 2: Financial Performance - In 2024, *ST Muban reported a revenue of 277 million yuan, a staggering decline of 83.24% year-on-year, with a net loss of 1.162 billion yuan, marking a 4208.14% decrease compared to the previous year [8][10]. - The photovoltaic segment was the primary contributor to the financial downturn, with its revenue dropping by 76.73% and a gross margin of -65.98%, a decrease of 74.22 percentage points [10]. Group 3: Recent Developments and Risks - In Q1 2025, the company continued to experience a downward trend, with revenue falling by 59.28% to 6.028 million yuan and a net loss of 99.486 million yuan, alongside a gross margin of -91.14% [11]. - The company is facing liquidity issues, with judicial deductions of funds amounting to 42.545 million yuan due to contractual disputes, totaling 122 million yuan in deductions and 34.881 million yuan frozen [13]. - Due to negative profit and revenue below 300 million yuan, *ST Muban's stock is under delisting risk, with additional warnings due to internal control issues [13].

【环球网财经综合报道】日前，有6家*ST公司发布公告称，收到《终止上市事先告知书》，其中5家触及财务类强制退市指标，1家触及交易类强制退市指 标。 具体来看，*ST中程5月7日公告称，公司收到深交所下发的《终止上市事先告知书》，拟被终止股票上市交易。此前，*ST中程因2023年度经审计的期末净 资产为负值，股票交易已被实施退市风险警示。2024年年度报告显示，公司财务会计报告被出具保留意见的审计报告，财务报告内部控制被出具否定意见的 审计报告，触及深交所《股票上市规则（2025年修订）》相关股票终止上市情形。 *ST人乐于5月6日公告称，公司收到《终止上市事先告知书》，深交所拟决定终止其股票上市交易。因2023年度经审计的净资产为负值，公司股票已被实施 退市风险警示。2024年度，公司经审计的期末净资产为-4.04亿元，财务会计报告被出具无法表示意见的审计报告，财务报告内部控制被出具否定意见的审 计报告，触及深交所相关股票终止上市情形。 *ST工智也因2024年度财务会计报告被出具无法表示意见的审计报告，财务报告内部控制被出具否定意见的审计报告，收到《终止上市事先告知书》。公司 5月9日晚公告称，已在规定期限 ...

Core Viewpoint - Renrenle, known as the "first private supermarket stock," is set to delist from the A-share market due to significant financial losses and negative net assets [1][4]. Financial Performance - In 2024, Renrenle reported revenue of approximately 1.43 billion yuan, a drastic decline of 49.86% year-on-year, with total assets decreasing by 50.94% [5]. - The company's net assets were reported at around -404 million yuan, marking a continued trend of financial distress [5][6]. - The company had previously forecasted a net profit of 410 million to 460 million yuan for 2024, but the actual results showed a loss of 17.3 million yuan, indicating a significant discrepancy [5][6]. Historical Context - Established in 1996, Renrenle was once a leading retail enterprise in Shenzhen, competing with major players like Walmart and Carrefour [3]. - The company had a history of generating over 10 billion yuan in revenue annually after going public in 2010, but has faced continuous losses in recent years [3][4]. Operational Changes - Renrenle has been struggling with operational challenges, having closed 45 stores and transferred 15 stores while only opening one new store during the reporting period [8]. - The company has attempted various strategies for recovery, including asset sales and business adjustments, but has not yet achieved a turnaround [7]. Leadership Changes - The chairman of Renrenle, Hou Yankui, resigned on March 19, 2025, due to health reasons, relinquishing all his positions within the company [1][8].

Core Viewpoint - The increasing prevalence of "non-standard audit opinions" is becoming a significant indicator for delisting in the A-share market, reflecting ongoing improvements in the quality of financial information disclosure among listed companies [1][5]. Group 1: Non-Standard Audit Opinions - As of now, 191 out of 5403 listed companies in the A-share market received "non-standard audit opinions" for their 2024 annual reports, a decrease of 7.3% from 206 companies in 2023 [1][5]. - The breakdown of non-standard opinions includes 20 companies with "unable to express an opinion," 99 with "emphasis of matter" in unqualified opinions, and 72 with qualified opinions [1][2]. - The introduction of internal control audits for the ChiNext and Beijing Stock Exchange has led to 155 internal control non-standard opinions, with 38 companies receiving "negative opinions" [1][2]. Group 2: Audit Firms and Reasons for Non-Standard Opinions - A total of 44 accounting firms issued the 191 non-standard audit opinions, with Zhongxing Caiguanghua leading with 20 opinions, followed by Lixin with 16 [2]. - The primary reasons for non-standard opinions include uncertainties regarding business authenticity, limitations in audit scope, and significant doubts about the company's ability to continue as a going concern [2][3]. - Specific cases, such as *ST Dongtong and *ST Xinyuan, illustrate the challenges faced by companies in providing adequate audit evidence and the impact of ongoing investigations on audit outcomes [2][3]. Group 3: Delisting Risks - Companies receiving "unable to express an opinion" or "negative opinions" face delisting risks under the stock listing rules, with 20 companies already under delisting risk warnings [5][6]. - A total of 98 companies have received non-standard opinions for two consecutive years, with five companies facing potential delisting due to repeated "unable to express an opinion" reports [5][6]. - The new delisting regulations effective from January 1, 2025, may also lead to forced delisting for companies with three consecutive years of internal control non-standard opinions [6][7]. Group 4: Recommendations for Companies - Companies are advised to disclose the specifics and reasons for non-standard audit opinions promptly and to implement corrective measures [7][8]. - Maintaining close communication with audit firms and providing sufficient explanations and evidence for audit concerns can help mitigate the risks of receiving non-standard opinions in the future [7][8].